LEB

Taco John's® to Share Taco Tuesday; Issues Challenge to Competitors (and LeB***) to Support Workers, Not Lawyers

Retrieved on: 
Tuesday, July 18, 2023
Taco John's, Patent, Injury, Friends, Parent, United States Patent and Trademark Office, Taco Tuesday, Cheese, Lawyer, Movement, Taco Bell, LEB, Child, Box, Hotel Employees and Restaurant Employees Union, CORE, Death, Mouth, Fast food, Taco

CHEYENNE, Wyo., July 18, 2023 /PRNewswire/ -- Taco John's, the home of Taco Tuesday for more than 40 years, will abandon the United States Patent and Trademark Office registration for its servicemark on the popular food holiday Tuesday, July 18.

Key Points: 
  • Taco John's, the home of Taco Tuesday for more than 40 years, will abandon the food holiday trademark today.
  • "As we've said before, we're lovers, not fighters, at Taco John's.
  • We also invite Del Taco, Taco Bueno, Taco Cabana, Jack In The Box and mom and pop taco shops across the country that intend to use Taco Tuesday in the future to join us in this movement to support working families and donate to CORE."
  • Taco John's also encourages noted taco lover, Taco Bell spokesperson and prolific trademark owner LeB*** Ja*** to do his part by donating any fees he received from the latest multi-million-dollar Taco Bell Taco Tuesday ad campaign to CORE.

Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Retrieved on: 
Monday, May 1, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, The New England Journal of Medicine, AE, RAD, Face, Safety, Aes, Adherence, Atopic dermatitis, Dupilumab, Almirall, NEJM, Sample size determination, JAMA Dermatology, BJD, LEB, Advocate, Lilly, Patient, Common, Adolescence, Headache, Conjunctivitis, Abstract, Fertilizer, Pharmaceutical industry, Dermatology

This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.

Key Points: 
  • This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.
  • Safety among patients in ADvocate 1 and ADvocate 2 at one year was consistent with the induction phase of the trials and other lebrikizumab studies in AD, including ADhere.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Retrieved on: 
Monday, May 1, 2023
The New England Journal of Medicine, AE, RAD, Face, Safety, Aes, Adherence, Atopic dermatitis, Medicine, Dupilumab, Almirall, NEJM, Sample size determination, JAMA Dermatology, BJD, LEB, Advocate, Lilly, Patient, Common, Adolescence, Headache, Conjunctivitis, Abstract, Disease, Fertilizer, Pharmaceutical industry, Dermatology

This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.

Key Points: 
  • This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.
  • Safety among patients in ADvocate 1 and ADvocate 2 at one year was consistent with the induction phase of the trials and other lebrikizumab studies in AD, including ADhere.
  • Most AEs across the two studies were mild or moderate in severity, nonserious, and did not lead to treatment discontinuation.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.

BADGEPASS ONE INTEGRATION LAUNCHES CLOUD-BASED ACCESS CONTROL WITH SCHLAGE INTELLIGENT ELECTRONIC LOCKS & READERS

Retrieved on: 
Tuesday, January 10, 2023
Software, Allegion, EVP, LEB, RC, Maad a Sinig Kumba Ndoffene Fa Ndeb Joof, Schlage, Wi-Fi, Microsoft Store, RCS, ID, Video game console

CARMEL, Ind., Jan. 10, 2023 /PRNewswire/ -- Today, Allegion US, a leading provider of security products and solutions, announced its Schlage intelligent hardware integration with the BadgePass ONE platform. With this integration, BadgePass is the first to offer a subscription software package that includes all hardware and software needed to issue secure ID badges and manage door access privileges within a facility. It is also one of the first Reader Controller model integrations for Allegion, offering customers efficient, cost-effective access control implementations.

Key Points: 
  • It is also one of the first Reader Controller model integrations for Allegion, offering customers efficient, cost-effective access control implementations.
  • "The Schlage NDEB and LEB intelligent wireless locks are easy to install and seamlessly communicate with the software via Wi-Fi.
  • Allegion has supported successful integrations in two other BadgePass product lines: BadgePass Access Manager and TotalCard.
  • The new cloud access control integration is now available for download in the following app stores: Windows Store and iOS Store .